Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery

Age-related Cataract Clinical Trial

— GIST  

Official title:

Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04050644
• Other study ID #: S60915
• Status: Recruiting
• Phase: Phase 4
• Start date: October 30, 2018
• Est. completion date: December 2024

Study information

• Verified date: January 2023
• Source: Universitaire Ziekenhuizen KU Leuven
• Contact: Heleen Delbeke, MD
• Phone: +32 16 332687
• Email: heleen.delbeke[@]uzleuven.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare treatment with preservative-free dexamethasone 0.1% (Monofree Dexamethason) and diclofenac 0.1% (Dicloabak) eye drops versus preserved dexamethasone 0.1% (Maxidex) and diclofenac 0.1% (Voltaren Ophtha) eye drops after cataract surgery in terms of postoperative inflammation, iatrogenic dry eye disease and cystoid macular edema.

Description:

Cataract surgery is a standardized procedure yielding excellent visual outcomes in most patients. According to Daien et al., the incidence of cataract surgery in 2012 in France was 11/1000 person-years. Although there are few complications related to the surgery, patients often experience ocular discomfort in the postoperative period. Postoperative treatment usually includes topical non-steroidal anti-inflammatory drugs and topical steroids for four weeks to control anterior chamber inflammation, to relieve ocular pain after surgery and to reduce the incidence of cystoid macular edema. Benzalkonium chloride (BAK) is the most common eye drop preservative and is associated with several ocular adverse effects, including dry eye and ocular surface inflammation. Moreover, in two clinical trials comparing the effects of BAK-containing and preservative-free eye drops, anterior chamber inflammation was reported in response to BAK after 1 month of exposure. Finally, besides the fact that intra-ocular inflammation increases the risk of macular edema, there is some evidence in the literature suggesting that BAK may also contribute to the development of macular edema. Because of these well-established detrimental effects of preservatives, pharmaceutical industry has invested in the development of preservative-free eye drops in the past decade, which has led to preservative-free alternatives for almost all the eye medications. The aim of this project is to investigate whether omitting preservatives from the postoperative topical treatment after cataract surgery can reduce symptoms and signs of ocular surface disease, intra-ocular inflammation and the incidence of cystoid macular edema. Additionally ocular microbiome research is added to our study because of its known correlation with the ocular immunity. Although the ocular surface is continuously colonized by a commensal microbial community, the healthy ocular surface is not in an inflammatory state. This phenomenon suggests that there is an interplay between the ocular surface microbiome and innate immune mechanisms, which prevents inflammatory responses against commensal microbiota. St Leger et al. used a murine model to reveal the presence of a commensal, Corynebacterium mastitidis, on the ocular surface. Corynebacterium mastitidis elicited an IL-17 response from ƔΔT-cells, facilitating recruitment of neutrophils to the ocular surface and secretion of antimicrobial peptides in the tears. These findings suggest the presence of a functional resident microbiome on the ocular surface which contribute to immune homeostasis and protects the ocular surface from pathogens. Our expert in the area of ocular microbiome research is affiliated with the department of biochemistry and microbiology of the University of Ghent.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Patients diagnosed with age-related cataract
• Age 60 years or above

Exclusion Criteria:

• Unwilling to sign informed consent
• Pseudoexfoliation syndrome
• Functionally monocular patient
• Any use of eye drops during at least 3 months before surgery with the exception of artificial tears
• Pre-existing dry eye disease according to the criteria's of the TFOS DEXS II report
• Previous ocular surgery, laser treatment or uveitis, with the exception of retinal laser treatment (more than 6 months ago) and iridotomy (more than 6 months ago)
• Active conjunctivitis
• Wearing of contact lens
• Presence of any macular diseases possibly impacting visual acuity
• Presence of any ocular diseases leading to difficulty to have a correct eye examination
• Known or suspected allergy to any of the ingredients on the study medications
• Presence of uncontrolled systemic disease

Related Conditions & MeSH terms

• Age-related Cataract
• Capsule Opacification
• Cataract

Intervention

Drug:
• Preservative Free drop treatment
Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
• Preserved drop treatment
Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.

Locations

Country	Name	City	State
Belgium	Universitaire Ziekenhuizen Leuven	Leuven	Vlaams-Brabant
Belgium	AZ Delta	Roeselare	West-Vlaanderen

Sponsors (2)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen KU Leuven	Laboratoires Thea

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The superiority of treatment arm without conservative (WC) on treatment arm with conservative (C) on the aqueous flare value in the operated eye, measured with a laser flare meter, at week 4 after cataract surgery.	The Laser Flaremeter can measure the protein density in the anterior chamber by counting the photons. Flare Value is expressed in photoncount/ms. 1-9 photoncounts/ms is a normal value. Photoncount/ms from 10-500 is abnormal and indicates an inflamed eye.	4 weeks
Secondary	Tear Osmolarity	The difference in Tear Osmolarity between the two treatment arms. Tear Osmolarity value will be measured with TearLab.	4 weeks
Secondary	Conjunctival Hyperemia	The difference in Conjunctival Hyperemia between the two treatment arms. The scale that will be used is the Cornea and Contact Lens Research Unit (CCLRU) scale. Minimum score is 1, maximum score is 4.	4 weeks
Secondary	Corneal Fluorescein Staining	The difference in Corneal Fluorescein Staining between the two treatment arms. The grading scale that will be used is the Oxford grading scale. Minimum score is grade 0, maximum score is grade 5.	4 weeks
Secondary	Tear-film break up time	The difference in Tear-film break up time between the two treatment arms. The Tear-film break up time will be expressed in seconds.	4 weeks
Secondary	Corneal Sensitivity	The difference in Corneal Sensitivity between the two treatment arms. Corneal Sensitivity value will be measured with the Cochet-Bonnet Aesthesiometer, expressed in mm.	4 weeks
Secondary	Central macular thickness	The difference in Central Macular Thickness between the two treatment arms. Central Macular Thickness will be measured with OCT Cirrus, expressed in µm.	4 weeks
Secondary	DEQ-5 score	The difference in Five-item Dry Eye Questionnaire (DEQ-5) score between the two treatment arms. Minimum total score is 0, maximum total score is 22.	4 weeks
Secondary	Inflammatory cytokine activities in tears	The difference in Inflammatory cytokine activities in tears between the two treatment arms. The cytokines that will be measured are IL-1Bèta, TNF-Alpha, IL-6, IL-8, IL-17, INF ?, macrophage migration inhibitory factor,...	4 weeks
Secondary	Amount of tears	The difference in Amount of Tears between the two treatment arms. The Amount of Tears will be measured with Schirmer tear test strips. The strips will be placed in the lower eyelid pouch for 5 minutes, value is expressed in mm.	4 weeks